 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Laurus Labs' Synthesis segment is currently trading at a premium of more than 25 percent higher than Syngene. Considering the significant differences in their capabilities and size, the brokerage firm finds it hard to justify this premium.

Laurus Labs sinks 6% after Kotak Institutional Equities downgrades rating to 'sell'

The short to medium term trend of the Nifty index looks corrective till 19,234 followed by 18,887 levels.

Hot Stocks | Laurus Labs, PI Industries, IDBI Bank may deliver up to 14% in short term

Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 410 in its research report dated July 27, 2023.

Buy Laurus Labs; target of Rs 410: Motilal Oswal

Laurus Labs Standalone June 2023 Net Sales at Rs 1,107.65 crore, down 25.92% Y-o-Y

Laurus Labs registered an EBITDA margin of 14.1 percent in April-June, the lowest-ever on a quarterly basis.

Laurus Labs slips 2% on dismal earnings; brokerages foresee bleak growth

Revenue came in at Rs 1,181.8 crore, down 23.2 from the Rs 1,539 crore in the year-ago quarter

Laurus Labs Q1 results: Net profit tanks 88.8% to Rs 28.4 crore

The company has signed definitive agreements to acquire additional stake of 7.24% in Immunoadoptive Cell Therapy Private Limited (lmmunoACT)  for a cash consideration of Rs 80 crore.

Laurus Labs shares rise 3% after upping stake in gene therapy company

Engineers India stock has experienced a consolidation breakout on the daily chart, indicating a potential shift in its price trend.

Hot Stocks | Here is why you should bet on Engineers India, LIC Housing Finance, Laurus Labs in short term

Laurus Labs closes 1.3 percent higher at Rs 311.60, with volumes of 45.5 lakh shares. The stock has gained 6 percent in two sessions

Laurus Labs shares extend gains on USFDA approval for HIV drug

Sharekhan recommended Hold rating on Laurus Labs with a target price of Rs 338 in its research report dated April 28, 2023.

Hold Laurus Labs; target of Rs 338: Sharekhan

Laurus Labs Ltd. develops and manufactures active pharmaceutical ingredients for therapeutic areas of anti-retrovirals and hepatitis C. The company was founded by Dr. Satyanarayana Chava on September 19, 2005 and is headquartered in Hyderabad, India.

Watchers	2,596
52-Wk Low	278.85
52-Wk High	533.50

Market Cap	212.98B
Volume (M)	1.85M
52-Wk High	533.50
52-Wk Low	278.85

LAURUSLABS.NSE Laurus Labs Ltd.

About

Feed

News

Sentiment

Fundamentals